J7Z Panoramica delle azioni Jazz Pharmaceuticals plc identifica, sviluppa e commercializza prodotti farmaceutici per esigenze mediche insoddisfatte negli Stati Uniti, in Europa e a livello internazionale. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Jazz Pharmaceuticals plc Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Jazz Pharmaceuticals Prezzi storici delle azioni Prezzo attuale dell'azione US$115.30 Massimo di 52 settimane US$122.90 Minimo di 52 settimane US$92.40 Beta 0.56 Variazione di 1 mese -1.03% Variazione a 3 mesi 0.087% Variazione di 1 anno 1.45% Variazione a 3 anni -8.05% Variazione a 5 anni -10.62% Variazione dall'IPO 795.19%
Notizie e aggiornamenti recenti Bruce Cozadd to Retire as Chief Executive Officer of Jazz Pharmaceuticals plc Upon Appointment of Successor by the End of 2025 Dec 17
Jazz Pharmaceuticals plc to Showcase New Real-World Evidence Reinforcing Epidiolex (Cannabidiol) Benefits Dec 07
Jazz Pharmaceuticals plc Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include Zanidatamab-Hrii (Ziihera®?) Dec 05
Jazz Pharmaceuticals plc to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting Dec 03
Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC) Nov 21
New minor risk - Insider selling Nov 15 Vedi altri aggiornamenti Bruce Cozadd to Retire as Chief Executive Officer of Jazz Pharmaceuticals plc Upon Appointment of Successor by the End of 2025 Dec 17
Jazz Pharmaceuticals plc to Showcase New Real-World Evidence Reinforcing Epidiolex (Cannabidiol) Benefits Dec 07
Jazz Pharmaceuticals plc Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include Zanidatamab-Hrii (Ziihera®?) Dec 05
Jazz Pharmaceuticals plc to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting Dec 03
Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC) Nov 21
New minor risk - Insider selling Nov 15
Executive VP & Chief Legal Officer recently sold €426k worth of stock Nov 15
Third quarter 2024 earnings released: EPS: US$3.50 (vs US$2.33 in 3Q 2023) Nov 07
Jazz Pharmaceuticals plc Presents New Data at Psych Congress 2024 Confirming Xywav®? (Calcium, Potent, and Sodium Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia Nov 01
Jazz Pharmaceuticals plc to Report Q3, 2024 Results on Nov 06, 2024 Oct 24
Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (Lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Oct 15
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from FTSE All-World Index (USD) Sep 23
Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024 Sep 16
gJazz Pharmaceuticals plc to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex/Epidyolex®? (Cannabidiol) At the European Epilepsy Congress 2024 Sep 05
Jazz Pharmaceuticals plc Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies Aug 23
Second quarter 2024 earnings released: EPS: US$2.68 (vs US$1.63 in 2Q 2023) Aug 02
Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) announces an Equity Buyback for $500 million worth of its shares. Aug 02 Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) announces an Equity Buyback for $500 million worth of its shares. Aug 01
Jazz Pharmaceuticals plc Elect Laura Hamill to the Board of Directors Jul 26
Jazz Pharmaceuticals plc to Report Q2, 2024 Results on Jul 25, 2024 Jul 18
Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer Jul 11
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 2500 Growth Index Jul 03
Jazz Pharmaceuticals plc Provides Update on Phase 2b Trial of Investigational Suvecaltamide in Essential Tremor Jun 20
Jazz Pharmaceuticals plc, Annual General Meeting, Jul 25, 2024 Jun 06
New minor risk - Insider selling Jun 02
Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board Jun 02
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024 May 31
Jazz Pharmaceuticals plc Announces the U.S. Food and Drug Administration Accepted and Granted Priority Review of the Biologics License Application (BLA) for Zanidatamab May 30
Executive VP & Chief Legal Officer recently sold €509k worth of stock May 09
First quarter 2024 earnings released: US$0.23 loss per share (vs US$1.09 profit in 1Q 2023) May 02
Jazz Pharmaceuticals plc Affirms Earnings Guidance for the Full Year 2024 May 02
Jazz Pharmaceuticals plc to Report Q1, 2024 Results on May 01, 2024 Apr 19
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer Apr 02
Senior VP & Chief Accounting Officer recently sold €401k worth of stock Mar 13
Executive VP & CFO recently bought €1.3m worth of stock Mar 10
New minor risk - Earnings quality Mar 03
Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024 Feb 29
Full year 2023 earnings released: EPS: US$6.55 (vs US$3.58 loss in FY 2022) Feb 29
Jazz Pharmaceuticals Announces Board Changes Feb 27 Jazz Pharmaceuticals plc Appoints Philip Johnson as Executive Vice President, Effective March 1, 2024
Jazz Pharmaceuticals plc to Report Q4, 2023 Results on Feb 28, 2024 Feb 15
Insufficient new directors Jan 01
Kim Sablich to Departure as Executive Vice President and General Manager, US of Jazz Pharmaceuticals plc on December 31, 2023 Dec 16
Jazz Pharmaceuticals plc to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Annual Meeting Dec 02
Third quarter 2023 earnings released: EPS: US$2.33 (vs US$0.31 loss in 3Q 2022) Nov 09
Jazz Pharmaceuticals plc to Report Q3, 2023 Results on Nov 08, 2023 Oct 26
Jazz Pharmaceuticals plc Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xyw Oct 24
Jazz Pharmaceuticals plc to Present Data from Trials of Bispecific Antibody Zanidatamab and Zepzelca Oct 17
Jazz Pharmaceuticals plc Receives European Commission Approval for Enrylaze® for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Sep 22 Jazz Pharmaceuticals plc Announces Chief Financial Officer Changes, October 1, 2023
Jazz Pharmaceuticals plc Revises Earnings Guidance for the Year 2023 Aug 10
Second quarter 2023 earnings released: EPS: US$1.63 (vs US$0.56 in 2Q 2022) Aug 10
Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation Jul 30
Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation Jul 29
Jazz Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023 Jul 28
Jazz Pharmaceuticals plc, Annual General Meeting, Aug 03, 2023 Jun 17
Jazz Pharmaceuticals plc and Zymeworks Inc. Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers Jun 03
Jazz Pharmaceuticals plc Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023 Jun 01
Insider recently sold €734k worth of stock May 23
First quarter 2023 earnings released: EPS: US$1.09 (vs US$0.027 in 1Q 2022) May 11
Jazz Pharmaceuticals plc Affirms Revenue Guidance for the Year 2023 May 11
Insider recently sold €276k worth of stock Mar 15
Full year 2022 earnings released: US$3.58 loss per share (vs US$5.52 loss in FY 2021) Mar 03
Jazz Pharmaceuticals plc to Report Q4, 2022 Results on Mar 01, 2023 Feb 16
Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Phase 2 Trial Evaluating Zanidatamab in Her2-Expressing Metastatic Gastroesophageal Adenocarcinoma Jan 20
Insider recently sold €265k worth of stock Dec 16
Independent Non-Executive Director recently sold €62k worth of stock Dec 09
Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies Dec 06
Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes At the 2022 American Epilepsy Society Annual Meeting Nov 29
Independent Director recently sold €1.0m worth of stock Nov 27
Executive VP & Chief Legal Officer recently sold €480k worth of stock Nov 20
Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn) Nov 19
Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.86 loss in 3Q 2021) Nov 11
Jazz Pharmaceuticals plc Raises Earnings Guidance for the Full Year 2022 Nov 10
Jazz Pharmaceuticals plc to Report Q3, 2022 Results on Nov 09, 2022 Oct 27
Jazz Pharmaceuticals plc Reiterates Revenue Guidance for the Full Year 2022 Sep 08
Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex Epidyolex (Cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures Aug 19
Independent Director recently sold €176k worth of stock Aug 11
Second quarter 2022 earnings released: EPS: US$0.56 (vs US$6.11 loss in 2Q 2021) Aug 04
Jazz Pharmaceuticals plc Updates Earnings Guidance for the Year 2022 Aug 04
Jazz Pharmaceuticals plc to Report Q2, 2022 Results on Aug 03, 2022 Jul 21
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity Jun 29
Jazz Pharmaceuticals plc, Annual General Meeting, Jul 28, 2022 Jun 14
Jazz Pharmaceuticals plc Presents Positive Data from Phase 2/3 Trial of Rylaze (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma At the ASCO 2022 Annual Meeting Jun 08
Senior VP & Chief Accounting Officer recently sold €288k worth of stock May 13
First quarter 2022 earnings released: EPS: US$0.027 (vs US$2.16 in 1Q 2021) May 06
Jazz Pharmaceuticals plc Raises Financial Guidance for the Full Year 2022 May 05
Jazz Pharmaceuticals plc to Report Q1, 2022 Results on May 04, 2022 Apr 21
Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, Including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types Apr 09
Axsome Therapeutics, Inc. (NasdaqGM:AXSM) agreed to acquire Sunosi® from Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) for $53 million. Mar 29
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 03
Jazz Pharmaceuticals plc Provides Revenue Guidance for the Full Year 2022 Mar 03
Jazz Pharmaceuticals plc to Report Fiscal Year 2021 Results on Mar 01, 2022 Feb 16
Jazz Pharmaceuticals plc Completes U.S. FDA Supplemental Biologics License Application for Rylaze Feb 03 Rendimenti per gli azionisti J7Z DE Pharmaceuticals DE Mercato 7D -3.7% -5.2% 0.5% 1Y 1.5% -10.6% 15.3%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: J7Z ha superato il German Pharmaceuticals che ha restituito -10.6 % nell'ultimo anno.
Rendimento vs Mercato: J7Z ha avuto una performance inferiore al mercato German che ha registrato un rendimento 15.3 % nell'ultimo anno.
Volatilità dei prezzi Is J7Z's price volatile compared to industry and market? J7Z volatility J7Z Average Weekly Movement 4.0% Pharmaceuticals Industry Average Movement 5.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Prezzo delle azioni stabile: J7Z non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato German.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di J7Z è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Jazz Pharmaceuticals plc identifica, sviluppa e commercializza prodotti farmaceutici per esigenze mediche insoddisfatte negli Stati Uniti, in Europa e a livello internazionale. L'azienda offre Xywav per la cataplessia o l'eccessiva sonnolenza diurna (EDS) con narcolessia e ipersonnia idiopatica; Xyrem per il trattamento della cataplessia o dell'EDS con narcolessia; Epidiolex per le crisi epilettiche associate alle sindromi di Lennox-Gastaut e Dravet o al complesso della sclerosi tuberosa; Zepzelca per il trattamento del carcinoma polmonare a piccole cellule metastatico o con progressione della malattia durante o dopo la chemioterapia a base di platino; Rylaze per la leucemia linfoblastica acuta o il linfoma linfoblastico; Enrylaze per il trattamento della leucemia linfoblastica acuta e del linfoma linfoblastico; Defitelio per il trattamento della malattia veno-occlusiva epatica grave; e Vyxeos per la leucemia mieloide acuta di recente diagnosi correlata alla terapia. Sviluppa inoltre Zanidatamab per il trattamento dell'adenocarcinoma gastroesofageo (GEA) che esprime HER2 e dei pazienti con GEA metastatico che esprime HER2; Zepzelca per il trattamento di pazienti con tumori solidi selezionati recidivati/refrattari sulla base di una risposta limitata in tre coorti di tumori solidi; JZP815, un inibitore della chinasi pan-RAF che ha come bersaglio i componenti della proteina chinasi attivata dal mitogeno; JZP898, una molecola di interferone alfa ad attivazione condizionata; Epidiolex per il trattamento di LGS, DS e TSC; Suvecaltamide per il trattamento del tremore della malattia di Parkinson; JZP150, un inibitore dell'idrolasi degli acidi grassi per il trattamento del disturbo da stress post-traumatico; e JZP441 per il trattamento della narcolessia, dell'IH e di altri disturbi del sonno.
Mostra di più Jazz Pharmaceuticals plc Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Jazz Pharmaceuticals con la sua capitalizzazione di mercato? J7Z statistiche fondamentali Capitalizzazione di mercato €7.00b Guadagni(TTM ) €446.39m Ricavi(TTM ) €3.85b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) J7Z Conto economico (TTM ) Ricavi US$3.99b Costo del fatturato US$294.67m Profitto lordo US$3.70b Altre spese US$3.23b Guadagni US$463.16m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 7.66 Margine lordo 92.62% Margine di profitto netto 11.60% Rapporto debito/patrimonio netto 146.6%
Come si è comportato J7Z nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/02/07 15:09 Prezzo dell'azione a fine giornata 2025/02/06 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github .
Fonti analitiche Jazz Pharmaceuticals plc è coperta da 51 analisti. 19 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Joel Beatty Baird Ishan Majumdar Baptista Research Richard Silver Barclays
Mostra 48 altri analisti 
